The Readout Loud

STAT

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

  1. 3 DAYS AGO

    368: New stakes in the vaccine dispute and a boost for biotech

    Labor Day is in the rearview mirror, and that means Adam, Elaine, and Allison are all back to work. They take the pulse of the biotech market and discuss forthcoming data readouts at two sleep and lung disorder conferences. But first, they discuss the bubbling uncertainty in the vaccine field.

    27 min

  2. 28 AUG

    367: The ouster of CDC's director, biotech venture firm rankings

    We bring on Washington correspondent Chelsea Cirruzzo to explain the ouster of CDC Cirector Susan Monarez and the resignations of other top officials. We also chat about STAT's annual VC rankings report, as well as ongoing issues at a major drug manufacturing site that was owned by Catalent and now owned by Novo Nordisk.

    29 min

  3. 21 AUG

    366: Viking’s obesity flop, ‘pharma to table’ drug sales

    On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Therapeutics and the investor cult that embraces it, both of which performed a painful belly flop this week. Then, we’ll dish on the growing “pharm to table” movement. That’s the clever buzzphrase bandied around by Big Pharma insiders to promote plans that sell drugs directly to consumers — supposedly at lower costs that will make President Trump happy. Except as our cohost Elaine Chen reported this week, these direct-to-consumer plans championed by Eli Lilly, Novo Nordisk, Bristol Myers Squibb, and others are unlikely to make drugs more affordable. We’ll dig into the details.

    25 min

  4. 14 AUG

    365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

    We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to animal testing, and why they’re the subject of hot debate among scientists.

    28 min

  5. 7 AUG

    364: Closing a zombie biotech, and Lilly's disappointing obesity readout

    We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and her advice for other biotech CEOs. We also chat about a disappointing readout from Eli Lilly's key small molecule GLP-1 candidate, setbacks in Vertex's pain business, and the story behind Replimmune's recent FDA rejection.

    38 min

  6. 31 JUL

    363: What Vinay Prasad’s ouster means for biotech and the FDA

    This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s biologics division. This surprising development came after a series of controversial decisions he made on Sarepta’s gene therapy for Duchenne muscular dystrophy and a barrage of political attacks from conservative voices. We bring on Brian Skorney, senior research analyst at Baird, to talk about the implications for the biotech industry. We then have on Robert Califf, former FDA commissioner, and Ned Sharpless, former acting FDA commissioner, to discuss the implications for the agency.

    44 min

  7. 24 JUL

    362: A mother’s perspective on Sarepta’s gene therapy halt

    We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration. We also talk about a rare mega-round for a new oncology biotech and an emerging class of drugs aimed at helping people stay awake.

    37 min

  8. 17 JUL

    361: Inside an FDA drug rejection, and layoffs at Sarepta

    Just how many employees is Sarepta Therapeutics laying off? And why did the Food and Drug Administration reject Ultragenyx’s rare disease drug over manufacturing qualms? Ultragenyx CEO Emil Kakkis joins us to discuss what was in the rejection letter his company received late last week, and whether he still has confidence in FDA Commissioner Marty Makary. We also discuss Capricor’s drug rejection, and Sarepta’s decision to lay off hundreds of staffers, but give raises to some executives.

    43 min
See All (372)

Hosts & Guests

About

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Information

  • Creator
    STAT
  • Years Active
    2018 - 2025
  • Episodes
    372
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    The Readout Loud

You Might Also Like